OTCMKTS:PNEXF Pharnext (PNEXF) Stock Price, News & Analysis $400.00 0.00 (0.00%) As of 07/13/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pharnext Stock (OTCMKTS:PNEXF) Get Pharnext alerts:Sign Up Key Stats Today's Range$400.00▼$400.0050-Day Range$400.00▼$400.0052-Week Range$0.0001▼$0.0010Volume16,660 shsAverage Volume433 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pharnext SA (OTCMKTS:PNEXF) is a clinical‐stage biopharmaceutical company based in Paris, France, dedicated to developing innovative treatments for rare neurological and neuromuscular disorders. The company’s proprietary discovery platform, Pleotherapy, employs bioinformatics and machine learning to identify synergistic combinations of existing compounds, with the goal of accelerating drug development and improving patient outcomes. Pharnext’s lead candidate, PXT3003, is undergoing advanced clinical evaluation for Charcot‐Marie‐Tooth disease type 1A (CMT1A), a hereditary peripheral neuropathy. Additional programs include PXT864 for amyotrophic lateral sclerosis (ALS) and PXT258 for Alzheimer’s disease, each designed to leverage low‐dose combinations of approved drugs to enhance efficacy while minimizing safety risks. By focusing on repurposed agents, Pharnext aims to reduce the time and cost typically associated with novel drug discovery. Founded in 2007 as a spin‐off from French academic research, Pharnext has established collaborations with universities, non‐profit organizations and contract research organizations across Europe and North America. The company has conducted multi‐center clinical trials in several countries and is preparing regulatory submissions to expand access to its pipeline globally. Pharnext’s management team draws on extensive experience in drug development, translational research and regulatory affairs to advance its programs toward commercialization.AI Generated. May Contain Errors. Read More Receive PNEXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharnext and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PNEXF Stock News HeadlinesPharnext SA PNEXFAugust 2, 2024 | morningstar.comMPHARNEXT: Pharnext takes full stock of its operating, strategic and financial situationMarch 11, 2024 | finanznachrichten.deThis dark force is about to change everythingAn unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.October 16 at 2:00 AM | Porter & Company (Ad)Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1AFebruary 28, 2024 | actusnews.comPHARNEXT by Pharnext Stock (OTC:PNEXF), Insider Trading ActivityFebruary 25, 2024 | benzinga.comPHARNEXT: Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1AJanuary 17, 2024 | finanznachrichten.dePharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1AJanuary 17, 2024 | actusnews.comPharnext set to release pivotal trial data for CMT1A treatment PXT3003December 15, 2023 | investing.comSee More Headlines PNEXF Stock Analysis - Frequently Asked Questions How have PNEXF shares performed this year? Pharnext's stock was trading at $400.00 at the start of the year. Since then, PNEXF stock has increased by 0.0% and is now trading at $400.00. When did Pharnext's stock split? Pharnext shares reverse split on the morning of Thursday, February 15th 2024.The 1-10000 reverse split was announced on Thursday, February 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Pharnext? Shares of PNEXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:PNEXF CIKN/A Webwww.pharnext.com Phone(314) 109-2230FaxN/AEmployees23Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:PNEXF) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Final DisplacementA new documentary called The Final Displacement is stirring major controversy — and for good reason. It expose...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharnext SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharnext With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.